Skip to main content
SpringerLink
Log in
Book cover

Viral Hepatitis: Chronic Hepatitis B pp 95–103Cite as

Hepatitis D Virus Infection: Role of Hepatitis B and the Current Updates on Management

  • Chapter
  • First Online:

  • 688 Accesses

Abstract

Hepatitis D virus (HDV) discovery was linked to hepatitis B virus (HBV), where it was named as delta antigen and thereafter found to be the smallest RNA virus but a genome by itself depending of hepatitis B in its life cycle. It uses hepatitis B surface antigen as envelope and uses similar mechanism to enter the hepatocyte. Once inside the hepatocyte, it uses the host cell enzymes to replicate. HDV has eight genotypes with variation in geographic location and clinical severity. Also, certain HBV genotypes are linked with higher viral load and lower remission rates. Chronic hepatitis D (CHD) can result from either coinfection or superinfection of HBV, the latter associated with higher rate of progression to CHD. Pegylated interferon has been the mainstay treatment for CHD for many years with discouraging virological response around 25%. Recent trails of new medications including myrcludex B, lonafarnib, and nucleic acid polymers show some promising results awaiting further larger trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Smedile A, Rizzetto M. HDV: thirty years later. Dig Liver Dis. 2011;43(Suppl 1):S15–8.

    Article  PubMed  Google Scholar 

  3. Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8 Suppl:S10–4. discussion S21–3.

    Article  CAS  PubMed  Google Scholar 

  4. Ahn J, Gish RG. Hepatitis D virus: a call to screening. Gastroenterol Hepatol (N Y). 2014;10:647–86.

    Google Scholar 

  5. Amini N, Alavian SM, Kabir A, Aalaei-Andabili SH, Saiedi Hosseini SY, Rizzetto M. Prevalence of hepatitis d in the eastern Mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13:e8210.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat. 2011;18:518–24.

    Article  CAS  PubMed  Google Scholar 

  7. Rizzetto M, Alavian SM. Hepatitis delta: the rediscovery. Clin Liver Dis. 2013;17:475–87.

    Article  PubMed  Google Scholar 

  8. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–9.

    Article  PubMed  Google Scholar 

  9. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, Winters MA, Proudfoot J, Glenn JS. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013;28:1521–5.

    Article  PubMed  Google Scholar 

  10. Deny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol. 2006;307:151–71.

    PubMed  CAS  Google Scholar 

  11. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130:1625–35.

    Article  CAS  PubMed  Google Scholar 

  12. Wu JC, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet. 1995;346:939–41.

    Article  CAS  PubMed  Google Scholar 

  13. Casey JL, Niro GA, Engle RE, Vega A, Gomez H, McCarthy M, Watts DM, Hyams KC, Gerin JL. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis. 1996;174:920–6.

    Article  CAS  PubMed  Google Scholar 

  14. Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, Kazanji M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in Central Africa. J Clin Microbiol. 2008;46:754–6.

    Article  PubMed  Google Scholar 

  15. Kiesslich D, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, Diaz RS. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis. 2009;199:1608–11.

    Article  CAS  PubMed  Google Scholar 

  16. Lin JH, Chang MF, Baker SC, Govindarajan S, Lai MM. Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA. J Virol. 1990;64:4051–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  17. Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. 2016;64:S102–S16.

    Article  CAS  PubMed  Google Scholar 

  18. Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, Gerin JL, Houghton M. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol. 1988;62:594–9.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol. 2012;1:71–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol. 2013;5:666–75.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife. 2012;1:e00049.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, Urban S. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070–83.

    Article  CAS  PubMed  Google Scholar 

  23. Huang CR, Lo SJ. Evolution and diversity of the human hepatitis d virus genome. Adv Bioinforma. 2010;2010:323654.

    Article  CAS  Google Scholar 

  24. Lai MM. The molecular biology of hepatitis delta virus. Annu Rev Biochem. 1995;64:259–86.

    Article  CAS  PubMed  Google Scholar 

  25. Rizzetto M. The adventure of delta. Liver Int. 2016;36(Suppl 1):135–40.

    Article  CAS  PubMed  Google Scholar 

  26. Casey JL. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol. 2006;307:67–89.

    PubMed  CAS  Google Scholar 

  27. Otto JC, Casey PJ. The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. J Biol Chem. 1996;271:4569–72.

    Article  CAS  PubMed  Google Scholar 

  28. Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components of the hepatitis delta virus. Viruses. 2010;2:189–212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Patient R, Hourioux C, Sizaret PY, Trassard S, Sureau C, Roingeard P. Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking. J Virol. 2007;81:3842–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17:749–56.

    Article  CAS  PubMed  Google Scholar 

  31. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. Influence of delta infection on severity of hepatitis B. Lancet. 1982;2:945–7.

    Article  CAS  PubMed  Google Scholar 

  32. Govindarajan S, Chin KP, Redeker AG, Peters RL. Fulminant B viral hepatitis: role of delta agent. Gastroenterology. 1984;86:1417–20.

    PubMed  CAS  Google Scholar 

  33. Chen PJ, Chen DS, Chen CR, Chen YY, Chen HM, Lai MY, Sung JL. Delta infection in asymptomatic carriers of hepatitis B surface antigen: low prevalence of delta activity and effective suppression of hepatitis B virus replication. Hepatology. 1988;8:1121–4.

    Article  CAS  PubMed  Google Scholar 

  34. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Arico S, Calzia R, Picciotto A, Colombo M, Popper H. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983;98:437–41.

    Article  CAS  PubMed  Google Scholar 

  35. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–38.

    Article  PubMed  Google Scholar 

  36. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991;13:1052–6.

    Article  CAS  PubMed  Google Scholar 

  38. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995;15:45–52.

    Article  CAS  PubMed  Google Scholar 

  39. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, Ilter T, Batur Y. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10:721–6.

    PubMed  CAS  Google Scholar 

  40. Yurdaydin C, Idilman R. Therapy of delta hepatitis. Cold Spring Harb Perspect Med. 2015;5:a021543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H, HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97.

    Article  CAS  PubMed  Google Scholar 

  42. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP, HIDIT-1 Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.

    Article  CAS  PubMed  Google Scholar 

  43. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol. 2006;21:657–63.

    Article  CAS  PubMed  Google Scholar 

  44. Wedemeyer H, Yurdaydin C, Ernst S, Caruntu F, Carercu M, Kendal K, Akarca US, Selium G, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Onur K, Port K, Celen MK, Stift J, Heidrich B, Mederacke I, Hardtke S, Koch A, Dienes HP, Manns MP. 96 weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Hepatology. 2013;58:222–3.

    Article  CAS  Google Scholar 

  45. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48–64.

    Article  CAS  PubMed  Google Scholar 

  46. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65:490–8.

    Article  CAS  PubMed  Google Scholar 

  47. Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483–9.

    Article  CAS  PubMed  Google Scholar 

  48. Glenn JS. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol. 2006;307:133–49.

    PubMed  CAS  Google Scholar 

  49. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Yurdaydin C, Idilman R, Keskin O, Kalkan C, Karakaya MF, Caliskan A, Yurdcu E, Karatayli SC, Bozdayi M, Koh C, Heller T, Glenn J. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study. J Hepatol. 2017;66:S33–S4.

    Article  Google Scholar 

  51. Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013;57:5291–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Al-Mahtab M, Bazinet M, Vaillant A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One. 2016;11:e0156667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Bazinet M, Pantea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Krawczyk A, Vaillant A. Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection. J Hepatol. 2017;66:S256–S7.

    Article  Google Scholar 

  54. Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Krawczyk A, Karimzadeh H, Roggendorf M, Vaillant A. FRI-105 - update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2A in caucasian patients with chronic HBV/HDV co-infection. J Hepatol. 2016;64:S584–S5.

    Article  Google Scholar 

  55. Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Vaillant A. LBP-507 - one year follow-up and HBV RNA/HBcrAg analysis in the REP 301 trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV/HDV co-infection. J Hepatol. 2017;66:S96–S7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA

    Abdulmajeed A. Albarrak, Ky-Dieu Tran & Veysel Tahan

Authors
  1. Abdulmajeed A. Albarrak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ky-Dieu Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Veysel Tahan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Veysel Tahan .

Editor information

Editors and Affiliations

  1. Cerrahasa Medical School, Istanbul University, Istanbul, Turkey

    Resat Ozaras

  2. University of Missouri, Columbia, Missouri, USA

    Veysel Tahan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Albarrak, A.A., Tran, KD., Tahan, V. (2018). Hepatitis D Virus Infection: Role of Hepatitis B and the Current Updates on Management. In: Ozaras, R., Tahan, V. (eds) Viral Hepatitis: Chronic Hepatitis B. Springer, Cham. https://doi.org/10.1007/978-3-319-93449-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93449-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93448-8

  • Online ISBN: 978-3-319-93449-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation